Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 5

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Pain 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × Radium-223 × Clear all
NCT04037358 2025-12-19

RAVENS

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
64 enrolled 25 charts
Genitourinary

Prostatic Neoplasms

NCT03093428 2025-03-28

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Dana-Farber Cancer Institute

Phase 2 Completed
45 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT03002220 2024-12-11

EXCAAPE

MedSIR

Phase 2 Completed
52 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT02278055 2023-04-07

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
29 enrolled 10 charts
Genitourinary

Pain, Prostatic Neoplasms

NCT02463799 2021-07-08

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
36 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡